A pediatric formulation of nifurtimox demonstrated superiority 1 year after treatment compared with placebo, according to results of a phase 3 clinical trial presented at a conference in Spain.
Creating pediatric formulations with appealing taste and appearance has been a challenge since drugs were developed specifically for children. With regulations in the United States and Europe now ...
Historically, it has been challenging to treat paediatric HIV patients because children require special medicine formulations. The FDA's tentative approval through the President's Emergency Plan for ...
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug ...
Leiden, The Netherlands, November 21, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been dosed in its Phase ...
Pediatric populations represent the most diverse patient groups in all of medicine. Factors such as individual preferences, physiology, and dosage considerations all serve to complicate drug ...
The FDA has drafted new recommendations on the development of drugs to treat pediatric patients with HIV meant to be applied on a global scale. The FDA has drafted new recommendations for the ...
The media have been replete with reports of ways in which the pharmaceutical industry has been able to increase revenue from medications that have been available for decades. 1 We report a new ...
The US Food and Drug Administration (FDA) has approved a new granulated formulation of the proton-pump inhibitor rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results